Akero Therapeutics, Inc.
Akero Therapeutics, Inc. (AKRO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AKRO · as of Mar 31, 2025
Ownership Breakdown
257
Institutional Holders
▲ 54 vs Q4
$3.50B
Total Inst. Value
▲ $1.44B vs Q4
82.32M
Shares Outstanding
freeFloat 86.38%
86.44M
13F Shares Held
▲ 12.24M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AKRO largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RTW INVESTMENTS, LP pharmaceutical preparations | 7.42M | 9.43% | 9.43% | $300.33B | May 15, 2025 | ▲ 559.5K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 7.07M | 8.99% | 8.99% | $301.92B | May 15, 2025 | ▲ 1.03M |
BLACKROCK, INC. pharmaceutical preparations | 6.26M | 7.95% | 7.95% | $253.20B | May 2, 2025 | ▲ 330.8K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 5.94M | 7.55% | 7.55% | $240.30B | May 13, 2025 | ▼ 1.44M |
GENERAL ATLANTIC, L.P. pharmaceutical preparations | 5.23M | 6.65% | 6.65% | $211.87B | May 14, 2025 | — held |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 4.82M | 6.12% | 6.12% | $195.00B | May 14, 2025 | ▲ 495.1K |
VANGUARD GROUP INC pharmaceutical preparations | 4.23M | 5.38% | 5.38% | $171.26B | May 9, 2025 | ▲ 526.2K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 3.21M | 4.08% | 4.08% | $129.95B | May 15, 2025 | ▲ 1.72M |
STATE STREET CORP pharmaceutical preparations | 2.49M | 3.17% | 3.17% | $100.99B | May 15, 2025 | ▲ 158.8K |
UBS GROUP AG pharmaceutical preparations | 2.16M | 2.74% | 2.74% | $87.29B | May 13, 2025 | ▲ 1.78M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
27
Increased
+12.53M shares9
New Positions
first time holders12
Decreased
−4.74M shares0
Sold Out
fully exitedNet shares change (top 50)
+7.79M
+12.53M / −4.74M
Net new holders
+24
9 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AKRO insider trading · insider activity
Source: SEC Form 4
20
Buy transactions
112
Sell transactions
0.18
Buy/Sell ratio
$5M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Heyman Tomas J. director | Dec 9, 2025 | D-Return | 13,000 | $26.32 | $342.2K | 0 | Form 4 ↗ |
Heyman Tomas J. director | Dec 9, 2025 | D-Return | 26,000 | $23.02 | $598.5K | 0 | Form 4 ↗ |
Heyman Tomas J. director | Dec 9, 2025 | D-Return | 15,000 | $50.83 | $762.5K | 0 | Form 4 ↗ |
Heyman Tomas J. director | Dec 9, 2025 | D-Return | 15,000 | $8.13 | $122.0K | 0 | Form 4 ↗ |
Heyman Tomas J. director | Dec 9, 2025 | D-Return | 9,398 | — | — | 0 | Form 4 ↗ |
Xu Yuan director | Dec 9, 2025 | D-Return | 9,398 | — | — | 0 | Form 4 ↗ |
Xu Yuan director | Dec 9, 2025 | D-Return | 15,000 | $50.83 | $762.5K | 0 | Form 4 ↗ |
Xu Yuan director | Dec 9, 2025 | D-Return | 15,000 | $8.13 | $122.0K | 0 | Form 4 ↗ |
Xu Yuan director | Dec 9, 2025 | D-Return | 13,000 | $26.32 | $342.2K | 0 | Form 4 ↗ |
Xu Yuan director | Dec 9, 2025 | D-Return | 26,000 | $28.79 | $748.5K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Akero Therapeutics, Inc. (AKRO) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 13.62%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Akero Therapeutics, Inc. is RTW INVESTMENTS, LP, holding approximately 7.42 million shares — equal to 9.43% of outstanding shares — as of March 31, 2025.
A total of 257 institutional investors currently hold AKRO stock, with a combined institutional value of approximately $3.50 billion as of the most recent 13F filing period.
Frequently asked questions
AKRO ownershipAkero Therapeutics, Inc. (AKRO) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is RTW INVESTMENTS, LP with a 9.43% stake. Company insiders hold 13.62%. Data sourced from SEC Form 13F as of March 31, 2025.